CENCINI, EMANUELE
 Distribuzione geografica
Continente #
NA - Nord America 2.175
EU - Europa 1.697
AS - Asia 268
AF - Africa 10
SA - Sud America 6
OC - Oceania 4
Totale 4.160
Nazione #
US - Stati Uniti d'America 2.171
GB - Regno Unito 630
IE - Irlanda 371
CN - Cina 206
SE - Svezia 193
IT - Italia 163
UA - Ucraina 125
FR - Francia 80
DE - Germania 52
FI - Finlandia 43
TR - Turchia 28
VN - Vietnam 17
BE - Belgio 14
AT - Austria 6
IN - India 6
KE - Kenya 6
PL - Polonia 6
RU - Federazione Russa 6
AU - Australia 4
CA - Canada 4
JP - Giappone 4
EG - Egitto 3
IR - Iran 3
RO - Romania 3
AR - Argentina 2
CL - Cile 2
HK - Hong Kong 2
NL - Olanda 2
BR - Brasile 1
ES - Italia 1
IM - Isola di Man 1
NG - Nigeria 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 4.160
Città #
Southend 594
Fairfield 389
Dublin 370
Ashburn 202
Chandler 170
Woodbridge 170
Houston 143
Seattle 138
Ann Arbor 135
Wilmington 129
Cambridge 120
Jacksonville 106
Siena 65
Princeton 63
Dearborn 60
Beijing 47
Nanjing 44
Izmir 28
Menlo Park 25
San Mateo 22
Boardman 21
Helsinki 19
Dong Ket 16
Brussels 14
Lappeenranta 13
Hefei 11
Nanchang 11
San Diego 11
New York 9
Shanghai 9
Florence 8
Jinan 8
Kunming 8
Shenyang 8
Tianjin 8
Guangzhou 7
Changsha 6
Hebei 6
Jiaxing 6
Nairobi 6
Vienna 6
London 5
Cagliari 4
Fuzhou 4
Kilburn 4
Ningbo 4
Philadelphia 4
Rome 4
Scarperia 4
Cairo 3
Chicago 3
Detroit 3
Hounslow 3
Melbourne 3
New Bedfont 3
Norwalk 3
Redwood City 3
San Francisco 3
Taizhou 3
Toronto 3
Venezia 3
Washington 3
Bari 2
Busto Arsizio 2
Campi Bisenzio 2
Falls Church 2
Genova 2
Hiroshima 2
Hong Kong 2
Milan 2
Prescot 2
The Dalles 2
Treviso 2
Zhengzhou 2
Acton 1
Albignasego 1
Amsterdam 1
Andover 1
Baotou 1
Belgrade 1
Bologna 1
Bonndorf 1
Buenos Aires 1
Buffalo 1
Castellammare Di Stabia 1
Cerveteri 1
Changchun 1
Chengdu 1
Chiswick 1
Cluj-Napoca 1
Colle Di Val D'elsa 1
Cormeilles-en-Parisis 1
Delhi 1
Düsseldorf 1
Groningen 1
Gunzenhausen 1
Haikou 1
Hangzhou 1
Ho Chi Minh City 1
Hunedoara 1
Totale 3.353
Nome #
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 318
New perspectives for patients with primary CNS lymphoma 171
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 166
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab 163
IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications 157
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 155
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 148
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 146
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 146
Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab 145
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 141
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 140
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 140
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 137
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib 136
Primary Nasopharyngeal Hodgkin Lymphoma 135
Prognostic role of m2 Tumour-Associated macrophages in lymphoproliferative disorders 134
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review 133
Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma 132
Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma 127
Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma 126
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 119
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma 116
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 105
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 98
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 97
Coexistence of Serum Monoclonal Gammopathy of Uncertain Significance and Hodgkin Lymphoma 89
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 81
How to manage early-stage follicular lymphoma 70
Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma? 60
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 54
Correction to: IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications (Virchows Archiv, (2020), 477, 1, (143-150), 10.1007/s00428-019-02712-8) 49
Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series 47
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 22
Two secondary localisation of non-Hodgkin's lymphomas in the upper gastrointestinal tract 20
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 17
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network) 15
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 14
Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center Study 12
Tp53 disruptions: Is there a marker of poor prognosis in chronic lymphoproliferative disorders? 6
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi 2
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone 2
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network) 2
Totale 4.293
Categoria #
all - tutte 13.763
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.763


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019351 0 0 0 0 0 0 0 0 0 0 196 155
2019/2020976 118 38 49 110 61 108 94 114 105 89 43 47
2020/2021856 34 55 100 67 62 80 77 111 62 82 64 62
2021/2022476 29 47 34 47 31 27 15 15 24 48 54 105
2022/2023636 34 62 85 73 77 130 17 43 63 6 24 22
2023/2024537 20 15 35 58 14 125 220 10 8 32 0 0
Totale 4.293